The global metabolic disorder therapeutics market is estimated to grow at a CAGR of 7.8% during the forecast period. An increasing number of clinical trials have been witnessed over the years owing to the rising prevalence of metabolic disorders and increasing demand for more effective treatment. For instance, in May 2020, POXEL SA, a biopharmaceutical company focused to develop innovative treatments for metabolic disorders, such as non-alcoholic steatohepatitis (NASH) and type 2 diabetes declared new preclinical results for PXL770. It is a direct adenosine monophosphate-activated protein kinase(AMPK) activator, was assessed in a rodent NASH model along with other major agents in development, such as a thyroid receptor ? agonist (MGL-3196), an FXR agonist (obeticholic acid), and a GLP-1 receptor agonist (semaglutide).
To Request a Sample of our Report on Global Metabolic Disorder Therapeutics Market: https://www.omrglobal.com/request-sample/metabolic-disorder-therapeutics-market
The outcomes feature PXL770 as a potential new NASH therapy that may develop complementary advantages while combined with other agents with different action mechanisms. Further, in September 2020, Kaleido Biosciences, Inc. declared that it has evaluated Microbiome Metabolic Therapy (MMT) candidate KB295 in the first patient suffering from mild-to-moderate ulcerative colitis. Such kinds of clinical studies are offering an opportunity for new launches of innovative therapies for metabolic disorders, which in turn, will further accelerate the market growth.
Scope of the Global Metabolic Disorder Therapeutics Market
Market Coverage
· Market number available for 2019-2026
· Base year- 2019
· Forecast period- 2020-2026
· Segment Covered- By Therapy and Disease
· Regions Covered- North America, Europe, Asia-Pacific, and Rest of the World
· Competitive Landscape- AbbVie, Inc., Novo Nordisk A/S, Sanofi SA, Boehringer Ingelheim GmbH, and AstraZeneca plc
Recent Strategic Initiatives in the Global Metabolic Disorder Therapeutics Market
· In March 2020, AstraZeneca plc declared the collaboration with Silence Therapeutics for discovery, development, and commercialization of small interfering RNA (siRNA) therapeutics to treat CVD, respiratory, renal, and metabolic disorders. This multi-target partnership will use the established small interfering RNA (siRNA) platform of Silence to detect and progress liver-based targets and develop new delivery methods to target other tissues including the heart, kidney, and lung.
· In March 2020, Eli Lilly and Co. declared the global licensing and research partnership with Sitryx, a biopharmaceutical company engaged in the development of therapeutics in immuno-inflammation and immuno-oncology. Under the partnership, the companies will study up to four new preclinical targets that are identified by Sitryx that could result in potential new medicines for autoimmune diseases. Lilly will make a $10 million equity investment in Sitryx and Sitryx will get an upfront payment of $50 million.
Key questions addressed by the report
· What is the market growth rate?
· Which segment/region dominates the market in the base year?
· Which segment/region will project the fastest growth in the market?
· How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected region/segment
· Who is the leader in the market?
· How players are addressing challenges to sustain growth?
· Where is the investment opportunity?
·
(Get 15% Discount on Buying this Report)
A full Report of Global Metabolic Disorder Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/metabolic-disorder-therapeutics-market
Global Metabolic Disorder Therapeutics Market-Segmentation
By Therapy
· Drug Therapy
· Gene Therapy
· Cellular Transplantation
· Enzyme Replacement Therapy
· Others
By Disease
· Obesity
· Diabetes
· Lysosomal Storage Disease
· Hypercholesterolemia
· Others
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
